Efficacy and Safety of Artemether-Lumefantrine in Treating Malaria in Nigerian Children
Author Information
Author(s): Falade Catherine O, Ogunkunle Oluwatoyin O, Dada-Adegbola Hannah O, Falade Adegoke G, de Palacios Patricia Ibarra, Hunt Philip, Virtanen Mailis, Oduola Ayoade M, Salako Lateef A
Primary Institution: University College Hospital, Ibadan, Nigeria
Hypothesis
The six-dose regimen of artemether-lumefantrine is safe and effective for treating acute uncomplicated malaria in Nigerian infants and children.
Conclusion
The six-dose regimen of artemether-lumefantrine is safe and effective for treating acute uncomplicated malaria in Nigerian infants and children weighing between five and 25 kg.
Supporting Evidence
- Day 14 cure rates for the intent to treat population were 95.1%.
- The six-dose regimen was well tolerated with no drug-related serious adverse events.
- Mean fever clearance time was 24.9 hours.
- Mean parasite clearance time was 26 hours.
- Overall PCR corrected day 28 cure rate was 95.1% for the intent to treat population.
Takeaway
This study shows that a medicine called artemether-lumefantrine works well and is safe for treating malaria in young children.
Methodology
An open label, non-comparative trial assessed the efficacy and safety of six-dose regimen of AL tablets in 103 Nigerian infants and children suffering from acute uncomplicated malaria.
Limitations
The study was conducted in a single location and may not be generalizable to all populations.
Participant Demographics
The study included 103 children aged between five weeks and nine years, with a near-equal gender distribution (50 males and 53 females).
Statistical Information
Confidence Interval
(80.8–97.8)
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website